alternatives to glp-1 agonists The and Obesity: How Diabetes Drugs are Changing Non-Diabetic Lives — tl;dr pharmacy GLP-1 Agonists Market Growth and

Specifically, we applied genetic proxies for l-carnitine to genome-wide association studies (GWAS) of CVD and its risk factors (type 2 diabetes, glucose, HbA1c, insulin, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides, apolipoprotein B, and blood pressure)

It's a close cousin to the more widely known GHK-Cu, but with its own unique properties and research applications, particularly within the scope of Hair & Skin Research

References 1.Unger RH, Scherer PE

De Vos M, Mielants H, Cuvelier C et al (1996) Long-term evolution of gut inflammation in patients with spondyloarthropathy